KHRNF - Khiron Life Sciences Corp.
| Previous Close | 0.6900 |
| Open | 0.6990 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.6685 - 0.7068 |
| 52 Week Range | 0.5919 - 3.2800 |
| Volume | 127,954 |
| Avg. Volume | 189,384 |
| Market Cap | 77M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3020 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
Uruguay Senate Approves New Bill To Regulate Access To Medical Cannabis
To help put a definitive end to persisting illicit cannabis markets, Uruguay's senate has passed a new bill to regulate medical marijuana. The bill, "A Comprehensive Law for the Promotion and Access to Medical and Therapeutic Cannabis," was introduced into Congress by the "Ir" sector of the “Frente Amplio” party, and approved unanimously. The new bill also presents guidelines for pharmaceutical compounding.
- CNW Group
Khiron Welcomes Legalization of Medical Cannabis in Brazil
Khiron Welcomes Legalization of Medical Cannabis in Brazil
- PR Newswire
Khiron Announces Chairman Transition and Appointment of Audit Committee Chair
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that Sidney Himmel has resigned as Director and Chair of the Board to pursue other interests, effective immediately.
- Simply Wall St.
We Think Khiron Life Sciences (CVE:KHRN) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- PR Newswire
Khiron Announces Option and Restricted Share Unit Grants
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America announced that it has granted stock options and restricted share units (RSUs) to certain directors and officers of the Company and its subsidiaries under the Company's Amended and Restated Stock Option Plan and Amended and Restated RSU Plan.
- Benzinga
Khiron Life Sciences Announces Wider Year-Over-Year Net Loss, Says Cash Position Strong
Khiron Life Sciences Corp (OTC: KHRNF) (CSE: KHRN) reported third-quarter revenue of CA$2.8 million ($2.1 million) on Tuesday and a CA$47.9 million cash balance. The company announced a net loss for the quarter of CA$10.6 million, or CA$0.09 per share, versus a net loss of CA$5.2 million in the third quarter of 2018.
- CNW Group
Khiron Reports Q3 Fiscal 2019 Financial Results, With $47.9 Million Cash Balance and $2.8 Million in Quarterly Revenue
22 cannabis strains registered in Colombia and in Q3 successfully harvested a number of these strains, converting to an extract. TORONTO , Nov. 26, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America announced today its financial results for the third quarter ended September 30, 2019 .
- Market Exclusive
Khiron Becomes First Colombian Firm to Commercialize THC Cannabis
Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) has received approval for commercial production of psychoactive, high-THC cannabis for both domestic and export purposes. The Colombian Technical Quotas Group (TQG) has authorized the company to cultivate and commercialize up to 560 kg or approximately, 65,000 units of psychoactive, high-THC cannabis in 2019. The authorization makes Khiron the first […]The post Khiron Becomes First Colombian Firm to Commercialize THC Cannabis appeared first on Market Exclusive.
- Benzinga
Khiron Becomes First Company In Colombia To Obtain Approval To Commercialize High-THC Cannabis
Vertically integrated company Khiron Life Sciences Corp. (TSXV:KHRN), (OTC: KHRNF) announced Monday it has received authorization to commercialize psychoactive, high-THC cannabis for both domestic and export purposes. Khiron is the first and only cannabis company in Colombia to obtain this approval. The company said this authorization is due to commercial quotas provided to Khiron by the Colombian Technical Quotas Group, which allow the company to grow and commercialize around 65,000 units of psychoactive, high-THC cannabis in 2019, with first commercial cultivation planned to start in the fourth quarter.
- CNW Group
Khiron Receives First Colombian Authorization to Commercialize High-THC Cannabis for Domestic and Export Sales
TORONTO , Nov. 25, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , today announced that it has become the first and to date, only cannabis company in Colombia authorized to commercialize psychoactive, high-THC cannabis for both domestic and export purposes. Representing a key milestone towards Khiron's stated timeline to bring medical cannabis options to market, the authorization comes as a result of commercial quotas allocated to Khiron by the Colombian Technical Quotas Group ("TQG"), which permit the Company to cultivate and commercialize up to 560 kg – or approximately, 65,000 units – of psychoactive, high-THC cannabis in 2019.
- PR Newswire
Khiron Director and 55th President of Mexico, Vicente Fox to Present Keynote at UK Cannabis Investor Conference
TORONTO, Nov. 21, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that Company Director and 55th President of Mexico, Vicente Fox, will present a keynote address at the Bryan, Garnier & Co Cannabis Conference, taking place on Thursday, November 28, 2019 in London, UK.
- PR Newswire
Khiron to be Exclusive Latin American Provider to Project Twenty21, Europe's Largest Medical Cannabis Study with 20,000 Patients
Khiron Life Sciences establishes early mover position to build its brand and product offering in the United Kingdom's nascent medical cannabis market Project Twenty21 will study medical cannabis's therapeutic ...
- CNW Group
Khiron Launches Kuida Brand in the US, Begins First Sales
TORONTO , Nov. 18, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , today announced the official launch of the Company's Kuida brand in the United States . Beginning this Wednesday, November 20 , Kuida's line of CBD skincare products will become available for purchase to US consumers at retail, initially in Los Angeles , before a planned expansion in priority US states where sale of hemp-derived CBD is permitted.
- Market Exclusive
Khiron Gets Approval to Bring Aceso Hemp Brand to Colombia
Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) is preparing to launch the Aceso Hemp brand in the Latin America market. Aceso will be the first brand to enter the Latin America market under the company's joint venture with Dixie Brands Inc. (CSE: Dixi.U). The company has received approval to sell Aceso Hemp in Colombia, […]The post Khiron Gets Approval to Bring Aceso Hemp Brand to Colombia appeared first on Market Exclusive.
- PR Newswire
Khiron Receives Approval to Sell Aceso™ Hemp CBD Brand in Colombia
First Hemp CBD brand to enter Latin American market under Dixie Brands joint venture Builds on proven Aceso brand acceptance across US consumer market Product line includes indication-specific (heat and ...
